Compare PHAR & GGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHAR | GGN |
|---|---|---|
| Founded | 1988 | 2005 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 877.0M |
| IPO Year | 2020 | N/A |
| Metric | PHAR | GGN |
|---|---|---|
| Price | $12.27 | $5.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $38.33 | N/A |
| AVG Volume (30 Days) | 10.1K | ★ 425.2K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.26% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.04 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.54 | $4.17 |
| 52 Week High | $21.34 | $5.88 |
| Indicator | PHAR | GGN |
|---|---|---|
| Relative Strength Index (RSI) | 31.36 | 40.10 |
| Support Level | $11.83 | $5.18 |
| Resistance Level | $17.29 | $5.32 |
| Average True Range (ATR) | 0.44 | 0.07 |
| MACD | -0.33 | 0.00 |
| Stochastic Oscillator | 22.05 | 2.29 |
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
GAMCO Global Gold Natural Resources & Income Trust is a non-diversified closed-end management investment company. Its primary investment objective is to provide a high current income and capital appreciation as its secondary objective. To achieve its objective, the fund may invest majority of its assets in equity securities of companies principally engaged in the gold and natural resources industries. It also intends to earn income through an option planning of writing (selling) covered call options on equity securities in its portfolio.